Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
Creating impact through fulfilling unmet medical need by
delivering innovative medicines to as many people possible
~290 million patients reached
with Innovative Medicines and
Novartis Global Health, and an additional
-453 million patients reached
with Sandoz
~150 pipeline projects
further expanding patient reach
~40 new drug approvals
over the last 20 years, delivering
innovative medicines
Recent innovation highlights:
LeqvioⓇ ASCVD
ScemblixⓇ CML
PluvictoⓇ
Prostate cancer
First gene, siRNA and
radioligand therapies
(at scale), fulfilling unmet medical need
iptacopan PNH and C3G
47 Investor Relations | Q4 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation